Sirona Biochem Corp.

SBM

CA82967M1005

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 03:44:08 2024-05-31 pm EDT			5-day change	1st Jan Change
0.055 ^CAD	+10.00%		-8.33%	-54.17%

May. 07	Sirona Biochem Engages Stonegate Healthcare Partners	CI
Apr. 08	Sirona Biochem Provides Update on Anti-Aging Product	MT

Sirona Biochem Corp. Announces Management Changes

June 23, 2014 at 05:00 pm EDT

Sirona Biochem Corp. announced that Neil Belenkie has resigned as Chief Executive Officer of the company. Neil has agreed to stay on with the company to assist in the transition until July 18, 2014.

Dr. Howard Verrico has been appointed interim CEO by the board of directors.

Latest news about Sirona Biochem Corp.

Sirona Biochem Engages Stonegate Healthcare Partners	May. 07	CI
Sirona Biochem Provides Update on Anti-Aging Product	Apr. 08	MT
Sirona Biochem Corp. announced that it has received CAD 0.1325 million in funding	Apr. 03	CI
Sirona Biochem Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024	Apr. 01	CI
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations	Mar. 13	MT
Sirona Biochem Corp. Reports Earnings Results for the Full Year Ended October 31, 2023	Feb. 28	CI
Sirona Biochem Corp. Announces Loan in the Aggregate Principal Amount of Up to $1,000,000	Jan. 29	CI
Sirona Biochem Initiated Private Placement	Jan. 29	MT
Sirona Biochem Corp. announced that it expects to receive CAD 1 million in funding	Jan. 28	CI
Sirona Biochem Corp. announced that it expects to receive CAD 1 million in funding	Jan. 25	CI
Sirona Biochem Corrects Earlier Statement	Jan. 24	MT
Sirona Biochem Provides Corporate Update	Jan. 24	MT
Sirona Biochem Launches Cosmetics Subsidiary	Jan. 15	MT
Sirona Biochem Corp. Introduces A Wholly-Owned Subsidiary Sirona Laboratories	Jan. 15	CI
Sirona Biochem Initiates GlycoProteMim Trademark for Anti-Aging Molecule TFC-1326	Dec. 11	MT
Sirona Biochem Corp. Initiates GlycoProteMim?? Trademark for Anti-Aging Molecule TFC-1326	Dec. 11	CI
Sirona Biochem Corp. Announces the Results of Its Research Collaboration with the International Centre for Genetic Engineering and Biotechnology in Advancing Sirona's Antiviral Compound Library	Nov. 29	CI
Sirona Biochem Announced Payment of Convertible Debenture Interests in Shares	23-10-20	MT
Sirona Biochem Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	23-09-29	CI
Sirona Biochem Provides Strategic Review Update	23-07-13	MT
Sirona Biochem Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	23-06-29	CI
Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing At the ICGEB	23-06-28	CI
Sirona Biochem to Present Anti-Aging Technology at BIO 2023 Conference in Boston	23-05-03	MT
Sirona Biochem Announces Exceptional Clinical Trial Results for Anti-Aging Compound TFC-1326	23-04-25	CI
Sirona Biochem Raises C$1.56 Million from a Private Placement of Convertible-Debenture Units	23-04-20	MT

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChemâs proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).

Sector

Biotechnology & Medical Research

Calendar

2024-06-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SIRONA BIOCHEM CORP.	-54.17%	10.34M
MODERNA, INC.	+43.34%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B